Compounding pathways, platform structures, and FDA strategy for the peptide market.
The peptide market is growing faster than the rules that govern it. FDA's Pharmacy Compounding Advisory Committee has been evaluating which peptides belong in the 503A compounding pathway, a docket that drew close to 2,000 public comments, and the rulemaking that follows could take one to two years. A federal-state Memorandum of Understanding on interstate distribution is on the horizon, and state boards are pushing for tighter guardrails. What is lawful today is substance-specific and date-specific.
Health Law Alliance advises the people building this market: 503A pharmacies, 503B outsourcing facilities, and the telehealth and wellness platforms that dispense through them. And when FDA or a state board starts asking questions, we defend the same programs we help design. The bench includes attorney and pharmacist Martha Rumore, a registered patent attorney with 200+ publications in FDA, DEA, and pharmacy law.
.png)
The commercial opportunity is real and so is the enforcement attention. Three exposures define the peptide market right now.
FDA polices adulteration, misbranding, and unapproved drug claims, and its inspection findings escalate from a Form 483 to a Warning Letter. State boards of pharmacy control the licenses. Marketing claims draw FTC and state attorney general attention, with product liability plaintiffs close behind. A peptide matter is rarely a one-regulator matter.
PCAC recommendations, Bulks List rulemaking, enforcement discretion categories, and a proposed interstate MOU are all in motion at once. A program that is compliant at launch can be offside within a quarter, and enforcement looks at the rule in effect on each dispense date. Programs need to be built for the rule that is coming, not just the one on the books today.
Prescriber independence, corporate practice of medicine, MSO fee design, anti-kickback exposure, and the compliance posture of the partner pharmacy. Enforcement and private litigation unwind sloppy structures long after launch, and restructuring under investigation costs multiples of structuring correctly.
Four structural features make peptide matters uniquely complex, and uniquely manageable if the program is designed around them.
Our bench includes Dr. Martha Rumore (pharmacist-attorney + registered patent attorney + 200+ publications in FDA, DEA, and pharmacy law) and a former Assistant U.S. Attorney nominated for the DOJ Director's Award. This is the protocol.
What you offer or plan to offer, the substances involved and their current federal status, the states in play, and the structure you operate through. The output is a concrete read on what is defensible today and what depends on pending rulemaking.
503A, 503B, or a vetted partner pharmacy. Prescriber and MSO structure for platform models. Sourcing standards and state licensure sequencing. Designed against cGMP, USP 797, and board expectations rather than around them.
Supplier qualification files and certificates of analysis, prescription-integrity documentation, marketing and claims sign-off, and the records a board or FDA will ask for first. If the program is ever inspected, the file answers before you do.
Form 483 responses, Warning Letter strategy, state board proceedings, and DEA coordination where controlled substances are involved, handled as one matter across every forum by the pharmacist-attorney and former-prosecutor bench.
If any of these describe your operation, assume you are visible to FDA and the state board whether or not anyone has contacted you yet.
Outcomes are summarized for confidentiality. Client names, precise geography, and identifying facts are redacted.
Form 483 Closed
A 503A compounding pharmacy received an FDA Form 483 with multiple observations following an unannounced inspection, including beyond-use date assignment challenges. HLA addressed each observation in a privileged 15-business-day written response with corrective action plans tied to the substantive USP 797 and DQSA framework. FDA closed the matter without escalating to a Warning Letter.
No Discipline
A compounding pharmacy was referred to the state board of pharmacy following a complaint regarding compounded GLP-1 dispensing during the FDA shortage period. HLA's response to the board reconstructed the dispense-date Bulks List status, the underlying patient-specific prescriptions, and the USP 797 compliance posture. The state board closed the matter with no discipline.
Resolved
A 503B outsourcing facility received FDA Inspectional Observations citing cGMP gaps in process validation and environmental monitoring. HLA coordinated the written response, the remediation plan, and the follow-on FDA communication. The matter resolved through documented remediation without escalation to a Warning Letter or consent decree.
Attorney advertising. Prior results do not guarantee a similar outcome. Case summaries are generalized for confidentiality and are not a substitute for legal advice on your specific matter.
Anthony's background as a former federal prosecutor and executive for major healthcare companies provided a level of expertise and insight that made all the difference. His deep understanding of healthcare law, particularly in litigation and compliance matters, helped navigate complex legal issues with ease.
Seven questions that come up on almost every first call.
Whether you are designing a peptide offering or answering a letter about one, have the privileged conversation first. We will tell you what is defensible, what is not, and what to fix before FDA or the board finds it. Free, confidential, no retainer.
